News AZ, Ionis build case for amyloidosis drug eplontersen Long-term data in ATTR polyneuropathy boost drug's credentials ahead of December FDA decision.
Patients CinCor Pharma: A small pharma’s journey to acquisition In this week's podcast, pharmaphorum welcomes Marc de Garidel, CEO of CinCor Pharma.
News AZ cancer drugs chalk up wins in early-stage lung cancer Tagrisso and Imfinzi show benefit as neoadjuvant and adjuvant therapy for patients with NSLC.
News Daiichi Sankyo wins round in Enhertu patent dispute US PTO has agreed to take another look at whether Seagen's '039 patent is valid.
News Lynparza under siege in first-line prostate cancer New data from Pfizer and J&J encroach on AZ and Merck's territory with the PARP inhibitor.
News NICE won’t back AZ’s Evusheld for COVID prevention Blood Cancer UK calls for help for the 'forgotten 500,000' who can't be protected with vaccines
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
